sub:assertion {
  <http://purl.obolibrary.org/obo/MONDO_0002046> biolink:category biolink:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/MONDO_0002046> ;
    rdf:predicate biolink:treats ;
    rdf:subject <https://identifiers.org/DRUGBANK:DB00657> ;
    a rdf:Statement ;
    rdfs:label "The nicotinic-acetylcholine receptor (nAchR)- antagonist mecamylanine has been found to reduce the stimulus produced by ethanol in human lab studies. The nAchR-antagonist varenicline has also displayed positive effect in reducing alcohol consumption in multiple clinical trials. In this 12- week double-blind trial, participants (n 1⁄4 126) were randomized to either mecamylamine (10 mg daily) or placebo. No medication effect was found for reducing heavy drinking days (HDD) or alcohol craving. Smoking status had no effect on the results. The authors suggest that broad-spectrum nAchR-antagonists may not be beneficial in treat- ing AUD" ;
    biolink:provided_by <https://w3id.org/um/NeuroDKG> ;
    biolink:publications <https://pubmed.ncbi.nlm.nih.gov/30973369> ;
    biolink:relation nkg:OffLabelIndication .
  <https://identifiers.org/DRUGBANK:DB00657> biolink:category biolink:Drug .
}